For postmenopausal women
with a recent osteoporotic fracture:
help Reduce the
Risk of Fractures1

Introducing TYMLOS, a new anabolic agent for osteoporosis that demonstrated1,2:

  • 86% relative risk reduction (RRR) in new vertebral fractures vs placebo (P<0.0001) and 3.6% absolute risk reduction (ARR) at 18 months1
  • 43% RRR in nonvertebral fractures vs placebo (P=0.049) and 2.0% ARR at
    19 months1*

Data included 18 months of treatment plus 1 month without treatment.1

See how TYMLOS affected the incidence of new vertebral fractures, nonvertebral fractures, and BMD

Discover the mechanism of action of abaloparatide 

Learn about the Together with Tymlos Patient Support program and savings card

References: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017. 2. Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2017;97:314-319.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.   All rights reserved.    08/17.   ABLSC-US-01042

This site is intended for HCPs in the United States.
TYMLOS is a trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.
All rights reserved. 08/17.
ABLSC-US-01042